Q-omics provides the consensus-scored NATP profile across patient tissues and cancer cell-line models. NATP expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NATP is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, NATP RNA expression shows 5,028 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, BRCA, and STAD as cancer lineages where NATP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NATP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NATP survival associations across molecular data types. NATP RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NATP RNA expression–survival associations across cancer types. High NATP expression shows unfavorable associations in BLCA, KIRC, ACC, UCEC and HNSC, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NATP RNA expression.
This table summarizes NATP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NATP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NATP shows lower tumor expression in LIHC and CHOL and higher tumor expression in BRCA. The BRCA box plot shows higher NATP RNA expression in tumor versus normal tissue (log2 FC = +0.339, t-test p < 0.001).
This table shows molecular features associated with NATP in patient tissues and cancer cell lines. In patient samples, NATP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
